FOMX - Foamix Pharmaceuticals Ltd.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.4200
-0.0200 (-0.58%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close3.4400
Open3.4300
Bid3.2000 x 1000
Ask3.4200 x 1800
Day's Range3.2100 - 3.4650
52 Week Range1.9700 - 4.4800
Volume977,461
Avg. Volume1,306,187
Market Cap209.488M
Beta (3Y Monthly)1.57
PE Ratio (TTM)N/A
EPS (TTM)-1.3100
Earnings DateNov 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.60
  • GlobeNewswire

    SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Merger of Menlo Therapeutics Inc. with Foamix Pharmaceuticals Ltd. is Fair to MNLO Shareholders

    NEW YORK, Nov. 13, 2019 -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Menlo Therapeutics Inc. (“Menlo” or.

  • SHAREHOLDER ALERT: WeissLaw LLP Investigates Foamix Pharmaceuticals Ltd.
    PR Newswire

    SHAREHOLDER ALERT: WeissLaw LLP Investigates Foamix Pharmaceuticals Ltd.

    NEW YORK , Nov. 12, 2019 /PRNewswire/ -- WeissLaw LLP  is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Foamix Pharmaceuticals Ltd. ("FOMX" ...

  • ACCESSWIRE

    FOAMIX PHARMACEUTICALS LTD. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Merger

    WILMINGTON, DE / ACCESSWIRE / November 12, 2019 / Rigrodsky & Long, P.A.: Do you own shares of Foamix Pharmaceuticals Ltd. (NASDAQ GS: FOMX )? Did you purchase any of your shares prior to November 11, ...

  • ACCESSWIRE

    MERGER INVESTIGATION ALERT: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders - KEM, FOMX, WLH

    NEW YORK, NY / ACCESSWIRE / November 11, 2019 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: KEMET Corporation (NYSE:KEM) The investigation ...

  • FOAMIX ALERT: Bragar Eagel & Squire, P.C. Investigates Proposed Sale of FOMX and Encourages Investors to Contact the Firm
    PR Newswire

    FOAMIX ALERT: Bragar Eagel & Squire, P.C. Investigates Proposed Sale of FOMX and Encourages Investors to Contact the Firm

    NEW YORK, Nov. 11, 2019 /PRNewswire/ -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder law firm, has launched an investigation into whether the board members of Foamix Pharmaceuticals Ltd. (FOMX) breached their fiduciary duties or violated the federal securities laws in connection with the company's proposed merger with Menlo Therapeutics. On November 11, 2019, Foamix announced that it had signed an agreement to merge with Menlo Therapeutics. Per the agreement, Foamix shareholders will receive 0.5924 shares of Menlo common stock for each share of Foamix common stock owned.

  • Thomson Reuters StreetEvents

    Edited Transcript of FOMX earnings conference call or presentation 11-Nov-19 1:30pm GMT

    Q3 2019 Foamix Pharmaceuticals Ltd Earnings Call and to Discuss Merger with Menlo Therapeutics Conference Call

  • GlobeNewswire

    Shareholder Investigation Alert: Halper Sadeh LLP Investigates Whether the Sale of These Companies is Fair to Shareholders – FOMX, CISN, PEGI, AXE

    NEW YORK, Nov. 11, 2019 -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Foamix Pharmaceuticals Ltd. (NASDAQ:.

  • MarketWatch

    Menlo, Foamix stocks set for selloffs after all-stock merger deal

    Shares of Menlo Therapeutics Ltd. was indicated down 14% in premarket trading Monday, and Foamix Pharmaceuticals Ltd. plunged 16%, after the company's announced a merger in which Foamix acquired Menlo in an all-stock deal. Under terms of the deal, each Foamix share will be exchanged for 0.5924 shares of Menlo common stock and a contingent stock right (CSR), which the companies said implies an 18% premium to Menlo's shareholders, based on the 10-day average volume-weighted price. Foamix shareholders will own 59% of the combined company. Menlo's lead product candidate, serlopitant, is being developed as a novel treatment for pruritus (itch), and Foamix's acne treatment Amzeeq has been approved by the Food and Drug Administration. If one of two of the phase 3 trials for serlopitant fails to meet its primary endpoint by May 31, 2020, Foamix shareholders will receive an additional 0.6815 of Menlo shares for each Foamix stock they own. If both phase 3 trials miss the primary endpoints, Foamix shareholders will receive an additional 1.2082 Menlo shares. Shares of Foamix have run up 56% over the past three months and Menlo soared 67%, while the S&P 500 has gained 6.0%.

  • Foamix (FOMX) Reports Q3 Loss, Misses Revenue Estimates
    Zacks

    Foamix (FOMX) Reports Q3 Loss, Misses Revenue Estimates

    Foamix (FOMX) delivered earnings and revenue surprises of -20.59% and -100.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Foamix Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    Foamix Pharmaceuticals Ltd. (FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, today announced financial results for the three and nine months ended September 30, 2019 and provided a corporate update. “The recent FDA approval of AMZEEQ™ for moderate-to-severe acne was a major milestone for Foamix as we transition to becoming a commercial stage organization. AMZEEQ is the first FDA approved topical form of minocycline and its approval represents a significant step in our goal of enhancing the standard of care for acne sufferers in the U.S.,” said David Domzalski, Chief Executive Officer of Foamix.

  • GlobeNewswire

    Foamix and Menlo Therapeutics to Merge, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic Indications

    Foamix Pharmaceuticals Ltd. (FOMX) (“Foamix”) and Menlo Therapeutics Inc. (MNLO) (“Menlo”) today announced that they have signed a definitive merger agreement to create a combined biopharmaceutical company focused on the commercialization and development of therapeutics to serve patients in the dermatology space. The Boards of Directors of both Foamix and Menlo have unanimously approved the transaction.

  • Benzinga

    The Week Ahead In Biotech: Adcom Test For Amarin's Fish Oil Pill, Agile Awaits FDA Verdict

    After the previous week's strong gains, biotech stocks experienced a slight loss of momentum this week. The week saw a few clinical trial readouts and a slew of earnings  reports from small- to mid-sized ...

  • GlobeNewswire

    Foamix Announces Issuance of New U.S. Patent for Compositions Combining a Retinoid and a Tetracycline Antibiotic

    Foamix Pharmaceuticals Ltd. (FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company, announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,463,742, reciting waterless compositions comprising a retinoid and a tetracycline antibiotic, as well as methods of using those compositions in treating dermatological disorders. This newly issued patent, which expires in 2030, is the latest U.S. patent to be issued to Foamix in connection with Foamix’s drug development programs for treating acne vulgaris. “We are delighted with the addition of this new patent, which provides additional coverage for our combination product candidate, FCD105, a topical foam for moderate-to-severe acne with a retinoid and minocycline,” said David Domzalski, Chief Executive Officer of Foamix.

  • Will Foamix (FOMX) Report Negative Earnings Next Week? What You Should Know
    Zacks

    Will Foamix (FOMX) Report Negative Earnings Next Week? What You Should Know

    Foamix (FOMX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Foamix Announces Publication of AMZEEQ™ (minocycline) Topical Foam Long Term Safety Data for Treatment Up to 1 Year in Journal of Clinical and Aesthetic Dermatology
    PR Newswire

    Foamix Announces Publication of AMZEEQ™ (minocycline) Topical Foam Long Term Safety Data for Treatment Up to 1 Year in Journal of Clinical and Aesthetic Dermatology

    REHOVOT, Israel, and BRIDGEWATER, N.J., Nov. 4, 2019 /PRNewswire/ -- Foamix Pharmaceuticals Ltd. (FOMX) (Foamix or the Company), a specialty pharmaceutical company, announced today the peer review publication of the long term open label safety portions of studies FX2014-04 and FX2014-05 (Studies 04 & 05) in the Journal of Clinical and Aesthetic Dermatology (JCAD). Studies 04 and 05 were conducted by Foamix to support the New Drug Application submission of AMZEEQTM (minocycline) topical foam, which was approved by the U.S. Food and Drug Administration (FDA) for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older. "Continuing from our earlier publication of Study FX2017-22 in the Journal of the American Academy of Dermatology, we are pleased that the Journal of Clinical and Aesthetic Dermatology has accepted these long-term safety data for publication," said David Domzalski, Chief Executive Officer of Foamix.

  • GlobeNewswire

    Foamix Pharmaceuticals to Report Third Quarter 2019 Financial Results on November 11

    REHOVOT, Israel and BRIDGEWATER, N.J., Nov. 01, 2019 -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on.

  • Will Foamix (FOMX) Report Negative Q3 Earnings? What You Should Know
    Zacks

    Will Foamix (FOMX) Report Negative Q3 Earnings? What You Should Know

    Foamix (FOMX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Have Insiders Been Buying Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) Shares?
    Simply Wall St.

    Have Insiders Been Buying Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) Shares?

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...

  • Navigating The Healthcare Industry: Science Fiction Turns to Reality
    Zacks

    Navigating The Healthcare Industry: Science Fiction Turns to Reality

    Kevin Cook joins us to help walk us through the maze that is the healthcare industry. We touch on everything from the hottest trends all the way down to how to pick a winning stock!

  • GlobeNewswire

    Foamix Enters Into Manufacturing and Supply Agreement For AMZEEQ™ and FMX103

    Foamix Pharmaceuticals Ltd. (FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company, today announced that it has entered into a long term contract manufacturing and supply agreement with ASM Aerosol-Service (“ASM”) for the Company’s recently approved AMZEEQ™ (minocycline) topical foam, 4% for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in adults and pediatric patients 9 years of age and older and for its product candidate FMX103 (minocycline) topical foam, 1.5% for the potential treatment of moderate to severe papulopustular rosacea in adults. Under the terms of the agreement, ASM will manufacture and supply AMZEEQ and FMX103 at its facility in Möhlin, Switzerland.

  • GlobeNewswire

    Foamix Announces Settlement of Litigation with Teva Relating to Finacea Foam

    Foamix Pharmaceuticals Ltd. (FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company, today announced that, together with LEO Pharma A/S (“LEO Pharma”) it has entered into a settlement and license agreement with an affiliate of Teva Pharmaceuticals Industries Ltd. (“Teva”) to resolve pending patent litigation involving Finacea® Foam. Details of the settlement agreement are confidential, and the settlement agreement is subject to the review of the Federal Trade Commission and the U.S. Department of Justice. This settlement comes after the settlement in April 2019 with affiliates of Perrigo Company plc relating to Finacea® Foam.

  • Foamix Receives FDA Approval of AMZEEQ™ Topical Minocycline Treatment for Millions of Moderate to Severe Acne Sufferers
    PR Newswire

    Foamix Receives FDA Approval of AMZEEQ™ Topical Minocycline Treatment for Millions of Moderate to Severe Acne Sufferers

    REHOVOT, Israel and BRIDGEWATER, N.J., Oct. 18, 2019 /PRNewswire/ -- Foamix Pharmaceuticals Ltd. (FOMX) ("Foamix" or the "Company"), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved its novel AMZEEQTM (minocycline) topical foam, 4%. AMZEEQ, formerly known as FMX101, is indicated for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in adults and pediatric patients 9 years of age and older and is the first topical minocycline to be approved by the FDA for any condition.

  • Foamix Announces FDA Acceptance of its New Drug Application for FMX103 Minocycline Foam for the Treatment of Moderate-to-Severe Papulopustular Rosacea
    PR Newswire

    Foamix Announces FDA Acceptance of its New Drug Application for FMX103 Minocycline Foam for the Treatment of Moderate-to-Severe Papulopustular Rosacea

    REHOVOT, Israel and BRIDGEWATER, N.J., Oct. 17, 2019 /PRNewswire/ -- Foamix Pharmaceuticals Ltd. (FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for FMX103 (minocycline topical foam 1.5%) topical foam. Foamix is seeking approval of FMX103 for the treatment of moderate-to-severe papulopustular rosacea in adults.